Inotiv, Inc. (NOTV)
USD 1.55
(3.33%)
USD 1.55
(3.33%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 572.42 Million USD | 4.52% |
| 2022 | 547.65 Million USD | 511.19% |
| 2021 | 89.6 Million USD | 48.18% |
| 2020 | 60.46 Million USD | 38.64% |
| 2019 | 43.61 Million USD | 65.55% |
| 2018 | 26.34 Million USD | 8.68% |
| 2017 | 24.24 Million USD | 18.59% |
| 2016 | 20.44 Million USD | -9.94% |
| 2015 | 22.69 Million USD | -7.67% |
| 2014 | 24.58 Million USD | 11.4% |
| 2013 | 22.06 Million USD | -21.77% |
| 2012 | 28.2 Million USD | -14.89% |
| 2011 | 33.14 Million USD | 15.16% |
| 2010 | 28.78 Million USD | -9.45% |
| 2009 | 31.78 Million USD | -23.77% |
| 2008 | 41.69 Million USD | -7.84% |
| 2007 | 45.24 Million USD | 5.1% |
| 2006 | 43.04 Million USD | 1.54% |
| 2005 | 42.39 Million USD | 14.11% |
| 2004 | 37.15 Million USD | 24.51% |
| 2003 | 29.83 Million USD | 12.54% |
| 2002 | 26.51 Million USD | 4.9% |
| 2001 | 25.27 Million USD | 31.48% |
| 2000 | 19.22 Million USD | -3.4% |
| 1999 | 19.9 Million USD | 9.34% |
| 1998 | 18.2 Million USD | 22.15% |
| 1997 | 14.9 Million USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 119.03 Million USD | -12.15% |
| 2024 Q3 | 105.78 Million USD | -11.13% |
| 2024 Q1 | 135.5 Million USD | -3.72% |
| 2023 Q2 | 151.46 Million USD | 23.39% |
| 2023 Q3 | 157.46 Million USD | 3.96% |
| 2023 Q4 | 140.74 Million USD | -10.62% |
| 2023 Q1 | 122.75 Million USD | -18.42% |
| 2023 FY | 572.42 Million USD | 4.52% |
| 2022 Q3 | 172.66 Million USD | 23.06% |
| 2022 Q1 | 84.21 Million USD | 179.99% |
| 2022 Q2 | 140.31 Million USD | 66.62% |
| 2022 FY | 547.65 Million USD | 511.19% |
| 2022 Q4 | 150.46 Million USD | -12.86% |
| 2021 Q1 | 17.88 Million USD | 13.38% |
| 2021 Q3 | 22.89 Million USD | 22.08% |
| 2021 FY | 89.6 Million USD | 48.18% |
| 2021 Q4 | 30.07 Million USD | 31.38% |
| 2021 Q2 | 18.75 Million USD | 4.84% |
| 2020 Q1 | 12.91 Million USD | -12.63% |
| 2020 Q4 | 15.77 Million USD | 0.06% |
| 2020 Q3 | 15.76 Million USD | -1.54% |
| 2020 FY | 60.46 Million USD | 38.64% |
| 2020 Q2 | 16.01 Million USD | 23.95% |
| 2019 Q1 | 8.62 Million USD | -4.02% |
| 2019 Q4 | 14.78 Million USD | 36.14% |
| 2019 FY | 43.61 Million USD | 65.55% |
| 2019 Q3 | 10.86 Million USD | 16.24% |
| 2019 Q2 | 9.34 Million USD | 8.34% |
| 2018 Q3 | 6.03 Million USD | 1.6% |
| 2018 Q1 | 5.37 Million USD | -8.45% |
| 2018 FY | 26.34 Million USD | 8.68% |
| 2018 Q4 | 8.98 Million USD | 48.8% |
| 2018 Q2 | 5.94 Million USD | 10.54% |
| 2017 Q3 | 5.83 Million USD | -8.22% |
| 2017 Q1 | 6.17 Million USD | 19.79% |
| 2017 FY | 24.24 Million USD | 18.59% |
| 2017 Q2 | 6.35 Million USD | 3.0% |
| 2017 Q4 | 5.87 Million USD | 0.63% |
| 2016 FY | 20.44 Million USD | -9.94% |
| 2016 Q2 | 5.33 Million USD | 9.07% |
| 2016 Q1 | 4.89 Million USD | -1.65% |
| 2016 Q3 | 5.05 Million USD | -5.36% |
| 2016 Q4 | 5.15 Million USD | 2.0% |
| 2015 Q1 | 5.84 Million USD | -8.96% |
| 2015 Q2 | 5.72 Million USD | -2.04% |
| 2015 Q3 | 6.15 Million USD | 7.4% |
| 2015 Q4 | 4.97 Million USD | -19.07% |
| 2015 FY | 22.69 Million USD | -7.67% |
| 2014 FY | 24.58 Million USD | 11.4% |
| 2014 Q4 | 6.42 Million USD | 6.43% |
| 2014 Q3 | 6.03 Million USD | 2.03% |
| 2014 Q2 | 5.91 Million USD | -4.95% |
| 2014 Q1 | 6.22 Million USD | 12.93% |
| 2013 FY | 22.06 Million USD | -21.77% |
| 2013 Q4 | 5.5 Million USD | -1.64% |
| 2013 Q3 | 5.6 Million USD | 8.61% |
| 2013 Q2 | 5.15 Million USD | -11.15% |
| 2013 Q1 | 5.8 Million USD | -11.27% |
| 2012 Q1 | 7.51 Million USD | -7.81% |
| 2012 Q3 | 7.18 Million USD | 3.16% |
| 2012 FY | 28.2 Million USD | -14.89% |
| 2012 Q2 | 6.96 Million USD | -7.32% |
| 2012 Q4 | 6.54 Million USD | -8.99% |
| 2011 Q2 | 8.42 Million USD | 4.12% |
| 2011 Q4 | 8.15 Million USD | -3.83% |
| 2011 Q1 | 8.09 Million USD | 9.25% |
| 2011 FY | 33.14 Million USD | 15.16% |
| 2011 Q3 | 8.47 Million USD | 0.65% |
| 2010 Q1 | 6.37 Million USD | -25.15% |
| 2010 Q2 | 6.93 Million USD | 8.75% |
| 2010 Q3 | 8.06 Million USD | 16.28% |
| 2010 FY | 28.78 Million USD | -9.45% |
| 2010 Q4 | 7.4 Million USD | -8.17% |
| 2009 Q4 | 8.52 Million USD | 4.91% |
| 2009 FY | 31.78 Million USD | -23.77% |
| 2009 Q1 | 8.07 Million USD | -13.94% |
| 2009 Q2 | 7.06 Million USD | -12.51% |
| 2009 Q3 | 8.12 Million USD | 14.93% |
| 2008 Q3 | 11.44 Million USD | 3.77% |
| 2008 Q4 | 9.38 Million USD | -18.02% |
| 2008 Q1 | 11.45 Million USD | 9.75% |
| 2008 Q2 | 11.03 Million USD | -3.68% |
| 2008 FY | 41.69 Million USD | -7.84% |
| 2007 Q2 | 11.31 Million USD | 3.92% |
| 2007 Q4 | 10.43 Million USD | -17.28% |
| 2007 Q3 | 12.61 Million USD | 11.53% |
| 2007 FY | 45.24 Million USD | 5.1% |
| 2007 Q1 | 10.88 Million USD | 1.26% |
| 2006 Q1 | 9.84 Million USD | -19.7% |
| 2006 Q2 | 12.41 Million USD | 26.14% |
| 2006 Q3 | 10.03 Million USD | -19.16% |
| 2006 Q4 | 10.74 Million USD | 7.08% |
| 2006 FY | 43.04 Million USD | 1.54% |
| 2005 Q1 | 9.69 Million USD | 6.61% |
| 2005 Q2 | 9.13 Million USD | -5.73% |
| 2005 Q3 | 11.3 Million USD | 23.69% |
| 2005 Q4 | 12.25 Million USD | 8.45% |
| 2005 FY | 42.39 Million USD | 14.11% |
| 2004 Q3 | 10.63 Million USD | 22.91% |
| 2004 Q1 | 8.77 Million USD | 9.15% |
| 2004 FY | 37.15 Million USD | 24.51% |
| 2004 Q4 | 9.09 Million USD | -14.48% |
| 2004 Q2 | 8.65 Million USD | -1.45% |
| 2003 Q2 | 6.95 Million USD | -0.34% |
| 2003 Q1 | 6.97 Million USD | 6.81% |
| 2003 FY | 29.83 Million USD | 12.54% |
| 2003 Q4 | 8.04 Million USD | 2.12% |
| 2003 Q3 | 7.87 Million USD | 13.29% |
| 2002 Q3 | 6.57 Million USD | -10.95% |
| 2002 Q4 | 6.52 Million USD | -0.71% |
| 2002 FY | 26.51 Million USD | 4.9% |
| 2002 Q2 | 7.38 Million USD | 22.61% |
| 2002 Q1 | 6.02 Million USD | -8.83% |
| 2001 Q4 | 6.6 Million USD | 3.23% |
| 2001 FY | 25.27 Million USD | 31.48% |
| 2001 Q3 | 6.4 Million USD | -6.46% |
| 2001 Q2 | 6.84 Million USD | 26.1% |
| 2001 Q1 | 5.42 Million USD | 3.62% |
| 2000 Q4 | 5.23 Million USD | -3.96% |
| 2000 Q2 | 4.09 Million USD | -7.05% |
| 2000 Q1 | 4.4 Million USD | -16.98% |
| 2000 Q3 | 5.45 Million USD | 33.3% |
| 2000 FY | 19.22 Million USD | -3.4% |
| 1999 Q3 | 5 Million USD | -1.96% |
| 1999 Q2 | 5.1 Million USD | 10.87% |
| 1999 Q1 | 4.6 Million USD | -6.12% |
| 1999 FY | 19.9 Million USD | 9.34% |
| 1999 Q4 | 5.3 Million USD | 6.0% |
| 1998 Q4 | 4.9 Million USD | 8.89% |
| 1998 Q1 | 4.3 Million USD | 9.69% |
| 1998 Q2 | 4.5 Million USD | 4.65% |
| 1998 FY | 18.2 Million USD | 22.15% |
| 1998 Q3 | 4.5 Million USD | 0.0% |
| 1997 FY | 14.9 Million USD | 0.0% |
| 1997 Q4 | 3.92 Million USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Aspira Women's Health Inc. | 9.15 Million USD | -6153.277% |
| bioAffinity Technologies, Inc. | 2.53 Million USD | -22503.168% |
| Intelligent Bio Solutions Inc. | 3.11 Million USD | -18295.414% |
| Standard BioTools Inc. | 106.34 Million USD | -438.297% |
| Prenetics Global Limited | 21.74 Million USD | -2532.726% |
| Neuronetics, Inc. | 71.34 Million USD | -702.3% |
| Star Equity Holdings, Inc. | 45.78 Million USD | -1150.246% |
| Castle Biosciences, Inc. | 219.78 Million USD | -160.444% |
| Psychemedics Corporation | 22.09 Million USD | -2490.393% |
| RadNet, Inc. | 1.61 Billion USD | 64.591% |
| Exact Sciences Corporation | 2.49 Billion USD | 77.101% |
| IDEXX Laboratories, Inc. | 3.66 Billion USD | 84.364% |
| iSpecimen Inc. | 9.92 Million USD | -5665.657% |
| OpGen, Inc. | 3.41 Million USD | -16645.799% |
| Exagen Inc. | 52.54 Million USD | -989.337% |
| Bionano Genomics, Inc. | 36.11 Million USD | -1484.962% |
| CareDx, Inc | 280.32 Million USD | -104.201% |
| Check-Cap Ltd. | - USD | -Infinity% |
| Twist Bioscience Corporation | 312.97 Million USD | -82.899% |
| Guardant Health, Inc. | 563.94 Million USD | -1.503% |
| Biodesix, Inc. | 49.08 Million USD | -1066.144% |
| BioNexus Gene Lab Corp. | 9.77 Million USD | -5758.524% |
| Precipio, Inc. | 15.19 Million USD | -3666.697% |
| Natera, Inc. | 1.08 Billion USD | 47.124% |
| Fulgent Genetics, Inc. | 289.21 Million USD | -97.925% |
| Sera Prognostics, Inc. | 306 Thousand USD | -186966.993% |
| 23andMe Holding Co. | 219.63 Million USD | -160.622% |
| OPKO Health, Inc. | 863.49 Million USD | 33.708% |
| Personalis, Inc. | 73.48 Million USD | -679.011% |
| Aclaris Therapeutics, Inc. | 31.24 Million USD | -1731.819% |
| Applied DNA Sciences, Inc. | 13.36 Million USD | -4182.233% |
| T2 Biosystems, Inc. | 7.19 Million USD | -7858.084% |
| Neogen Corporation | 924.22 Million USD | 38.064% |
| Myriad Genetics, Inc. | 678.4 Million USD | 15.621% |
| ICON Public Limited Company | 8.12 Billion USD | 92.951% |
| NeoGenomics, Inc. | 591.64 Million USD | 3.248% |
| Star Equity Holdings, Inc. | 45.78 Million USD | -1150.246% |
| MDxHealth SA | 70.19 Million USD | -715.502% |
| Prenetics Global Limited | 21.74 Million USD | -2532.726% |
| Illumina, Inc. | 4.5 Billion USD | 87.291% |
| DarioHealth Corp. | 20.35 Million USD | -2712.623% |
| ENDRA Life Sciences Inc. | - USD | -Infinity% |
| Medpace Holdings, Inc. | 1.88 Billion USD | 69.646% |
| Mainz Biomed B.V. | 895.47 Thousand USD | -63823.889% |
| Trinity Biotech plc | 56.83 Million USD | -907.223% |
| Sotera Health Company | 1.04 Billion USD | 45.446% |
| bioAffinity Technologies, Inc. | 2.53 Million USD | -22503.168% |